Neoadjuvant weekly carboplatin and paclitaxel followed by radical hysterectomy for locally advanced cervical cancer long-term results

International Journal of Gynecological Cancer

Volumn 20, Issue 4, 2010, Pages 611-616

  Mori, Taisuke ^a   Hosokawa, Kenichi ^a   Sawada, Morio ^a   Kuroboshi, Haruo ^a   Tatsumi, Hiroshi ^a   Koshiba, Hisato ^a   Okubo, Tomoharu ^a   Kitawaki, Jo ^a  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

Author keywords

Carboplatin; Cervical cancer; Neoadjuvant chemotherapy; Paclitaxel; Weekly schedule

Indexed keywords

CARBOPLATIN; PACLITAXEL;

ADULT; AGED; ALOPECIA; ARTICLE; BLOOD TOXICITY; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE CLEARANCE; DISEASE COURSE; FEMALE; FOLLOW UP; HUMAN; HYSTERECTOMY; LYMPH NODE METASTASIS; MULTIPLE CYCLE TREATMENT; NEUROPATHY; NEUTROPENIA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SURVIVAL RATE; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR VOLUME; UTERINE CERVIX CANCER;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, ADENOSQUAMOUS; CARCINOMA, SQUAMOUS CELL; COMBINED MODALITY THERAPY; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYSTERECTOMY; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; PACLITAXEL; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME; UTERINE CERVICAL NEOPLASMS;

EID: 77952253572     PISSN: 1048891X     EISSN: None     Source Type: Journal    
DOI: 10.1111/IGC.0b013e3181d80aa9     Document Type: Article

References (22)

1. Pisani P, Parkin DM. Estimates of the worldwide mortality from 25 cancers in 1990. Int J Cancer. 1999;83:18-29. (Pubitemid 29409471)
2. Mori T, Kinoshita Y, Watanabe A, et al. Retention of paclitaxel in cancer cells for 1 week in vivo and in vitro. Cancer Chemother Pharmacol. 2006;58:665-672.
3. Ozols RF. Paclitaxel (Taxol)/carboplatin combination chemotherapy in the treatment of advanced ovarian cancer. Semin Oncol. 2000;27:3-7.
4. Rose PG, Blessing JA, Gershenson DM, et al. Paclitaxel and cisplatin as first-line therapy in recurrent or advanced squamous cell carcinoma of the cervix: a gynecologic oncology group study. J Clin Oncol. 1999;17:2676-2680.
5. Katsumata N, Yasuda M, Takahashi F, et al. Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. Lancet. 2009;374:1331-1338.
6. Green MC, Buzdar AU, Smith T, et al. Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks. J Clin Oncol. 2005;23:5983-5992.
7. Sparano JA, Wang M, Martino S, et al. Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med. 2008;358:1663-1671.
8. Seidman AD, Berry D, Cirrincione C, et al. Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840. J Clin Oncol. 2008;26:1642-1649.
9. Duen'as-Gonzalez A, López-Graniel C, González-Enciso A, et al. A phase II study of multimodality treatment for locally advanced cervical cancer: neoadjuvant carboplatin and paclitaxel followed by radical hysterectomy and adjuvant cisplatin chemoradiation. Ann Oncol. 2003;14:1278-1284.
10. Neoadjuvant Chemotherapy for Locally Advanced Cervical Cancer Meta-analysis Collaboration. Neoadjuvant chemotherapy for locally advanced cervical cancer: a systematic review and meta-analysis of individual patient data from 21 randomised trials. Eur J Cancer. 2003;39:2470-2486.
11. Sardi J, Sananes C, Giaroli A, et al. Results of a prospective randomized trial with neoadjuvant chemotherapy in stage IB, bulky, squamous carcinoma of the cervix. Gynecol Oncol. 1993;49:156-165.
12. Leone B, Vallejo C, Perez J, et al. Ifosfamide and cisplatin as neoadjuvant chemotherapy for advanced cervical carcinoma. Am J Clin Oncol. 1996;19:132-135. (Pubitemid 26108214)
13. Aoki Y, Tomita M, Sato T, et al. Neoadjuvant chemotherapy for patients younger than 50 years with high-risk squamous cell carcinoma of the cervix. Gynecol Oncol. 2001;83:263-267.
14. Sugiyama T, Nishida T, Kumagai S, et al. Combination therapy with irinotecan and cisplatin as neoadjuvant chemotherapy in locally advanced cervical cancer. Br J Cancer. 1999;81:95-98.
15. Umesaki N, Fujii T, Nishimura R, et al. Phase II study of irinotecan combined with mitomycin-C for advanced or recurrent squamous cell carcinoma of the uterine cervix: the JGOG study. Gynecol Oncol. 2004;95:127-132.
16. Park DC, Suh MJ, Yeo SG. Neoadjuvant paclitaxel and cisplatin in uterine cervical cancer: long-term results. Int J Gynecol Cancer. 2009;19:943-947.
17. Keys HM, Bundy BN, Stehman FB, et al. Radiation therapy with and without extrafascial hysterectomy for bulky stage IB cervical carcinoma: a randomized trial of the Gynecologic Oncology Group. Gynecol Oncol. 2003;89:343-353.
18. Keys HM, Bundy BN, Stehman FB, et al. Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. N Engl J Med. 1999;340:1154-1161.
19. Horn LC, Fischer U, Raptis G, et al. Tumor size is of prognostic value in surgically treated FIGO stage II cervical cancer. Gynecol Oncol. 2007;107:310-315.
20. Delgado G, Bundy B, Zaino R, et al. Prospective surgical-pathological study of disease-free interval in patients with stage IB squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. Gynecol Oncol. 1990;38:352-357.
21. Goksedef BP, Kunos C, Belinson JL, et al. Concurrent cisplatin-based chemoradiation International Federation of Gynecology and Obstetrics stage IB2 cervical carcinoma. Am J Obstet Gynecol. 2009;200:175.e1-e5.
22. Koshiba H, Hosokawa K, Mori T, et al. Intravenous paclitaxel is specifically retained in human gynecologic carcinoma tissues in vivo. Int J Gynecol Cancer. 2009;19:484-488.